Peptide receptor radionuclide therapy in patients with metastatic progressive pheochromocytoma and paraganglioma: long-term toxicity, efficacy and prognostic biomarker data of phase II clinical trials

BACKGROUND: Pheochromocytoma and paraganglioma (PPGL) have currently only limited treatment options available for patients in the metastatic phase (mPPGL) in either post-surgery or inoperable settings. However, these rare tumors overexpress somatostatin receptors and can thus be treated with peptide...

Descripción completa

Detalles Bibliográficos
Autores principales: Severi, S., Bongiovanni, A., Ferrara, M., Nicolini, S., Di Mauro, F., Sansovini, M., Lolli, I., Tardelli, E., Cittanti, C., Di Iorio, V., Mezzenga, E., Scarpi, E., Ibrahim, T., Paganelli, G., Zovato, S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2021
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8219772/
https://www.ncbi.nlm.nih.gov/pubmed/34139487
http://dx.doi.org/10.1016/j.esmoop.2021.100171

Ejemplares similares

Ejemplares similares